OLD Mission Capital LLC trimmed its holdings in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 99.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,943 shares of the company's stock after selling 451,759 shares during the period. OLD Mission Capital LLC's holdings in AstraZeneca were worth $258,000 as of its most recent SEC filing.
Several other institutional investors have also recently bought and sold shares of the business. Albion Financial Group UT raised its position in AstraZeneca by 68.9% in the 4th quarter. Albion Financial Group UT now owns 608 shares of the company's stock worth $40,000 after purchasing an additional 248 shares during the last quarter. Versant Capital Management Inc raised its position in shares of AstraZeneca by 2,618.5% during the fourth quarter. Versant Capital Management Inc now owns 734 shares of the company's stock worth $48,000 after acquiring an additional 707 shares during the last quarter. Golden State Wealth Management LLC acquired a new position in shares of AstraZeneca during the fourth quarter valued at $55,000. Crews Bank & Trust bought a new position in AstraZeneca in the fourth quarter valued at about $55,000. Finally, Newbridge Financial Services Group Inc. acquired a new stake in AstraZeneca in the fourth quarter worth about $55,000. Institutional investors own 20.35% of the company's stock.
Analysts Set New Price Targets
A number of research firms have issued reports on AZN. UBS Group upgraded shares of AstraZeneca from a "neutral" rating to a "buy" rating in a research report on Thursday, February 13th. Morgan Stanley assumed coverage on shares of AstraZeneca in a report on Wednesday, February 12th. They issued an "overweight" rating on the stock. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $89.75.
Read Our Latest Report on AZN
AstraZeneca Trading Up 2.2 %
Shares of AZN stock traded up $1.42 on Friday, reaching $66.29. The company had a trading volume of 5,761,317 shares, compared to its average volume of 5,262,431. The stock has a market cap of $205.58 billion, a PE ratio of 29.33, a PEG ratio of 1.42 and a beta of 0.49. The company has a 50-day moving average of $73.35 and a 200-day moving average of $70.88. The company has a current ratio of 0.93, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65. AstraZeneca PLC has a 12 month low of $61.24 and a 12 month high of $87.68.
AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $1.05 EPS for the quarter, missing the consensus estimate of $1.10 by ($0.05). AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. On average, equities analysts forecast that AstraZeneca PLC will post 4.51 earnings per share for the current year.
AstraZeneca Increases Dividend
The firm also recently announced a semi-annual dividend, which was paid on Monday, March 24th. Shareholders of record on Friday, February 21st were issued a dividend of $1.03 per share. The ex-dividend date was Friday, February 21st. This is a positive change from AstraZeneca's previous semi-annual dividend of $0.49. This represents a yield of 2%. AstraZeneca's payout ratio is currently 91.15%.
AstraZeneca Company Profile
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Stories
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
